Shots:

• Juno to provide sales promotion and hospital contracting services to Australian Hospital market customers and will co-market Herzuma (biosimilar- trastuzumab) and Truxima (biosimilar- rituximab) with Celltrion in Australia
•  The focus of the agreement is to market globally biosimilar brands to Australian Healthcare professionals and patients
• Herzuma (CT-P6- biosimilar- trastuzumab) is a mAb targeting the extracellular domain of HER2 receptor and has received MFDS- EC and the FDA’s approval in Jan’2014- Feb’2018 and Dec’2018 respectively. Truxima is a mAb (CT-P10- biosimilar- rituximab) is a mAb approved in Korea in 2016- EU in Feb-2017 and is a novel biosimilar approved by Health Canada for NHL- CLL and RA

Click here to­ read full press release/ article | Ref: Juno Pharmaceuticals | Image: Celltrion